Skip to content

The effects of Prazosin in treating sleep problems of patients with post-stress traumatic disorder

Investigating the effectiveness of Prazosin for sleep problems of patients with post-stress traumatic disorder –chronic, war type

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013022512596N1
Enrollment
32
Registered
2013-05-07
Start date
2013-04-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: sleep problems. Condition 2: post traumatic stress disorder. Condition 3: sleep problems. Condition 4: sleep problems. nightmares Post-traumatic stress disorder sleep terrors Disorders of initiating and maintaining sleep [insomnias]

Interventions

Prazosin prescription: 1 mg 1 hour before sleep for 3 nights, then it increases up to 2 mg for seven nights. In the case of ineffectiveness and lack of counter-indications, the medication increases 2
unless, it increases up to 15 mg per night, in the case of lack of counter-indication..
Treatment - Drugs
unless, it increases up to 15 mg per night, in the case of lack of counter-indication.

Sponsors

Vice chancellor for research of Kermanshah University of Medical Sciences and Health Services
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients subject to post-stress traumatic disorder chronic war type according to DSM-IV-TR in a clinical interview by a psychiatrist, with sleep problems; Duration of the disorder is more than 6 months; participants' age is between 18 and 60 years (minimum of 18 years as a criterion of adulthood, and 60 years for the practicability of test taking). Exclusion criteria: history of mania, schizophrenia and other psychotic disorders; depression with suicide ideas; orthostatic hypotension and medicine sensitivity.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
PTST intensity. Timepoint: the start of the study, two months after the medication started. Method of measurement: the structured interview of CAPS-1.;Sleep problems. Timepoint: the start of the study, two months after the medication started. Method of measurement: the structured interview of CAPS-1, PCL questionnaire, Actigraph.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Habiballah Khazaie

Kermanshah university of medical science

hkhazaei@kums.ac.ir+98 83 1826 4512

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026